Preclinical and clinical studies of anticancer agent‐incorporating polymer micelles
Tóm tắt
The size of anticancer agent‐incorporating micelles can be controlled within the diameter range of 20–100 nm to ensure that they do not penetrate normal vessel walls. With this development, it is expected that the incidence of drug‐induced side‐effects may be decreased owing to the reduced drug distribution in normal tissue. Micelle systems can also evade non‐specific capture by the reticuloendothelial system because the outer shell of a micelle is covered with polyethylene glycol. Consequently, a polymer micelle carrier can be delivered selectively to a tumor by utilizing the enhanced permeability and retention effect. Moreover, a water‐insoluble drug can be incorporated into polymer micelles. Presently, several anticancer agent‐incorporating micelle carrier systems are under preclinical and clinical evaluation. Furthermore, nucleic acid‐incorporating micelle carrier systems are also being developed. (
Từ khóa
Tài liệu tham khảo
Matsumura Y, 1986, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res, 46, 6387
Kataoka K, 1993, Block copolymer micelles as vehicles for drug delivery, J Controlled Release, 24, 119, 10.1016/0168-3659(93)90172-2
Yokoyama M, 1991, Toxicity and antitumor activity against solid tumors of micelle‐forming polymeric anticancer drug and its extremely long circulation in blood, Cancer Res, 51, 3229
Carney DN, 1996, Chemotherapy in the management of patients with inoperable non‐small cell lung cancer, Semin Oncol, 23, 71
Roth BJ, 1996, Chemotherapy for advanced bladder cancer, Semin Oncol, 23, 633
Nishiyama N, 2003, Novel cisplatin‐incorporated polymeric micelles can eradicate solid tumors in mice, Cancer Res, 63, 8977
WilsonRH PlummerR AdamJet al.Phase I and pharmacokinetic study of NC‐6004 a new platinum entity of cisplatin‐conjugated polymer forming micelles.Am Soc Clin Oncol2008; (Abstract# 2573).
Takimoto CH, 2001, Cancer Chemotherapy and Biotherapy: Principal and Practice, 579
Slatter JG, 2000, Pharmacokinetics, metabolism, and excretion of irinotecan (CPT‐11) following I.V. infusion of [(14) C]CPT‐11 in cancer patients, Drug Metab Dispos, 28, 423
Sumitomo M, 2008, Novel SN‐38‐incorparated polymeric micelles, NK012, strongly supperss renal cancer progression, Cancer Res, 122, 2148
Nakajima‐Eguchi T, 2008, Antitumor effect of SN‐38‐releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastoric cancer in mice sompared with irinotecan, Caner Res
KatoK HamaguchiT ShiraoKet al.PhaseI study of NK012 polymer micelle SN‐38 in patients with advanced cancer.Proc Ams Soc Clin Oncol GI2008; (Abstract#485).
BurrisIIIHA InfanteJR SpigelDRet al.A phaseI dose‐escalation study of NK012.Proc Am Soc Clin Oncol2008; (Abstract#2538).
Matsumoto S, Environment‐responsive block copolymer micelles with a disulfide cross‐linked core for enhanced siRNA delivery, Biomaromolecules
Miyata K, Polyplex micelles from triblock copolymers composed of tandemly aligned segments with biocompatible, endosomal escaping, and DNA‐condensing functions for systemic gene delivery to pancreatic tumor, Pharm. Res